Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, announced it raised more than $13M in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.

Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health Ventures and several Angels. Ita Lu of Taiwania and Hamzeh Abdul-Hadi of Debiopharm will join Genialis' Board of Directors.